Business Development

EffRx is currently pursuing corporate development opportunities primarily to complement its pipeline, targeting late stage molecules, as well as to further expand the geographical footprint of Binosto.


1.     Licensing of late stage molecules for musculoskeletal, genitourinary and endocrine disorders to be further developed, approved and/or launched in Europe

    • Licensing of EU commercialization rights of late stage assets (Ph2/Ph3) by companies primarily focused on ex-EU markets
    • Co-development of late stage molecules, e.g. leveraging US data
    • Hybrid Go-To-Market collaborations for EU, leveraging EffRx set-up and infrastructure

2.      Licensing orphan products for Europe

    • In-licensing of European rights rights for orphan products in Phase 2/3
      (EffRx received an orphan drug designation (ODD) from FDA for the treatment of adolescent PCOS in May 2014)

3.      Licensing of Binosto® distribution rights in LATAM and other selected territories

EffRx seeks to further expand Binosto’s footprint to countries where the product is still unpartnered (see Binosto® Global Footprint), particularly:

    • LATAM distribution rights
    • US co-promotion rights